A coworking company and a real estate firm have been tapped by The Ion. Courtesy of Rice University

Last week, Rice Management Co. announced the latest partners for The Ion. A Houston-based real estate management firm and a Dallas-based coworking company have signed onto the project.

Texas coworking company Common Desk, which recently opened a new space in Houston's east downtown, was tapped to develop and manage The Ion's more than 58,000 square feet of experiential, flexible office space on the second floor of the building.

"For a project as special as The Ion, it was important that we selected a flexible office space operator that understood the building's ethos as a space for collaboration and innovation," says Ryan LeVasseur, managing director of Direct Real Estate at RMC, in a news release. "From the moment we met with the Common Desk team, it was clear they represented the right balance of sophistication and excitement and shared a commitment to creating a sense of community."

Additionally, Common Desk will be responsible for a coffee bar and maintaining a vibrant and engaging space for tenants, startups, and community members.

"We're thrilled to be a part of this prestigious project and are looking forward to offering individuals, small businesses, and high-growth companies the chance to experience the unique programming and innovative spirit of the building," says Dawson Williams, head of real estate at Common Desk, in the release. "We're excited to be a strategic gateway to helping Houstonians experience all The Ion has to offer."

RMC tapped Transwestern to oversee property management for all of The Ion through its building, tenant, vendor, compliance, client, and administrative services.

"Very few companies have Transwestern's breadth of experience and proven success of managing high-quality, talent-attracting workplaces," LeVasseur says in the release. "Add to that the company's deep roots in Houston, and we're confident we're working with the best team to ensure a flawless, attractive, activated, and efficiently operated hub for the growth of Houston's innovation ecosystem."

Based in Houston, Transwestern has over 400 properties locally across office, multifamily, health care, and other industries.

"Transwestern is excited to work alongside Rice Management Corporation as property and facilities manager for The Ion, while contributing to its mission of innovation, collaboration and inclusion," says Kevin Roberts, Southwest President at Transwestern, in the release. "As Transwestern continues to elevate our commitment to diversity, equity and inclusion, we are proud to stand alongside The Ion in supporting minority and women-owned businesses in enabling innovation that will shape the future of Houston."

Chevron has signed on to have space in The Ion. The company will also be a program partner. Photo courtesy of The Ion

Rising innovation hub announces Chevron as first tenant and program partner

eye on the ion

Chevron is the first tenant to sign a lease at The Ion, an innovation hub rising in Midtown Houston's former Sears building.

The Ion, a Rice Management Co. project expecting to premiere at 4201 Main St. in spring 2021, announced the new tenant and program partnership this week.

"Our first tenant at The Ion is one of the most recognizable brands in the world," says Ryan LeVasseur, managing director of Real Estate at Rice Management Co., in a news release. "We're thrilled to welcome Chevron into the Innovation District. They'll be the first of many companies, local startups, and business owners who make a home at and around The Ion as we continue to develop this groundbreaking, mixed-use space."

Chevron's Houston-based corporate investing arm, Chevron Technology Ventures, will be leading the space. The location can also be used by employees for networking, professional development and other opportunities within the innovation ecosystem.

"We are thrilled to support The Ion as a key component of Houston's growing innovation ecosystem," says Barbara Burger, president of CTV, in the release. "We have a long history in Houston with its role as the global energy capital. We believe The Ion will help to ensure that Houston retains that distinction and plays a leading role in the energy transition through innovation."

Founded in 1999, CTV has been an integral part of the Houston innovation ecosystem with its investment efforts and Catalyst Program. Recently, the group added two new startups to the accelerator.

CTV and Chevron in general have an existing relationship with The Ion and its team team, and Jan E. Odegard, interim executive director of The Ion, says he's excited for the relationship continue.

"By becoming our first tenant and a founding program partner, Chevron has shown it is committed to ensuring The Ion is Houston's premier destination for innovators, entrepreneurs, and academics to collaborate on workforce development, build tech-enabled businesses, and support the community," says Odegard in the release. "We're grateful to welcome such an esteemed organization to our space with which we share the same mission and values."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.